PATENT CLAIM ANALYSIS

Application Number: 15767813
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "027000"]

Abstract:
Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation using a combination of an inhibitor of a mutant IDH1 enzyme and an AML induction and consolidation therapy.

Claim (Index 3):
A method of treating AML, comprising administering to a subject a therapeutically effective amount of an isocitrate dehydrogenase 1 (IDH1) inhibitor and a combination of cytarabine and daunorubicin as an induction therapy, further comprising administering a combination of mitoxantrone and etoposide as a consolidation therapy, wherein the mutant IDH1 inhibitor is (S)\u2014N\u2014((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide, having the following formula: or a pharmaceutically acceptable salt, solvate, tautomer, stereoisomer, isotopologue, prodrug, or a polymorph thereof (COMPOUND 2), and wherein the AML is characterized by the presence of a mutant allele of IDH1.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 91.0
- Lexical Diversity: 1.26923
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15767822', '15125880', '15368405', '12730097', '12761588']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7112151747544619
- 35 USC 102 Novelty (BERT): 0.5284638983998869
- Combined Prediction Score: 0.6929400471190045
- Mean Citation Score: 284.5714260000001
- Max Citation Score: 329.0274
- Similarity Product: 247.00863435416213

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test